1 |
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN"> |
2 |
<html> |
3 |
<head> |
4 |
<title></title> |
5 |
<meta http-equiv="content-type" content="text/html; charset=ISO-8859-1"> |
6 |
</head> |
7 |
<body> |
8 |
<div align="Center"><b>State-of-the-art facility<br> |
9 |
<br> |
10 |
</b> |
11 |
<div align="Left"><i>Zagreb, 12 December 2001</i><br> |
12 |
<br> |
13 |
<div align="Center">Croatian Prime Minister Ivica Racan opens PLIVA’s new |
14 |
Oral Solid Dosage Forms facility<br> |
15 |
</div> |
16 |
</div> |
17 |
<br> |
18 |
</div> |
19 |
With the press of a button, Croatian Prime Minister Ivica Racan launched |
20 |
the automatically controlled vehicle, symbolically opening PLIVA’s new Oral |
21 |
Solid Dosage Forms facility, one of the state-of-the-art facilities for the |
22 |
production of oral solid drug forms in the world. Accompanying Prime Minister |
23 |
Racan were Croatian Minister of Health Andro Vlahucic, representatives from |
24 |
the Croatian Institute for Drug Control, the Croatian Institute for Health |
25 |
Insurance (HZZO), Faculty of Medicine and Faculty of Pharmacy and Biochemistry, |
26 |
whose hosts from PLIVA were CEO of PLIVA Zeljko Covic, members of PLIVA’s |
27 |
Management Board and the Oral Solid Dosage Forms Facility Project Director |
28 |
Zeljko Brebric. <br> |
29 |
<br> |
30 |
The total investment amounted approximately to HRK 640 million, which ranks |
31 |
PLIVA among the largest investors in Croatian economy, and the entire project, |
32 |
from the project beginning to full operation, lasted about three years.<br> |
33 |
<br> |
34 |
The plant was constructed in line with the highest international standards |
35 |
and is one of the most modern facilities in the world. Highly sophisticated |
36 |
equipment and level of automatization will significantly shorten the manufacturing |
37 |
process, enable the production of a range of various products and reduce |
38 |
production costs. The facility will manufacture more than 900 tons, or approximately |
39 |
2 billion tablets, coated tablets and capsules.<br> |
40 |
<br> |
41 |
The basic features of the new facility are automated transport of bulk substances, |
42 |
intermediaries and finished products as well as closed production areas completely |
43 |
aligned with the most demanding sanitary requirements, production conditions |
44 |
and personnel safety requirements. Seventy specially trained employees will |
45 |
be working in the new Oral Solid Dosage Forms facility. <br> |
46 |
<br> |
47 |
Part of the investment is the completely automated high-reach warehouse for |
48 |
starting material and intermediaries; a “pilot” plant where new drugs from |
49 |
PLIVA’s Development can be effectively reproduced in larger - semiindustrial |
50 |
amounts, at the same time ensuring the equal level of quality, enabling them |
51 |
to enter industrial manufacturing as such. In addition, the drug packaging |
52 |
plant has been completely renovated, new modern analytical laboratories have |
53 |
been built as well as a management and administration center and measurement |
54 |
and calibration center. <br> |
55 |
<br> |
56 |
The construction of PLIVA’s new facility lasted three years. The technological |
57 |
project was designed in cooperation with the Belgian consultant ELVECO, facility |
58 |
design and installation were performed by the Croatian company “Termoinzenjering” |
59 |
and construction was carried out by “Tehnika”. The general contractor for |
60 |
interior work and technical infrastructure was the Austrian company VATECH |
61 |
Elin EBG, whose most important subcontractors were the Croatian companies |
62 |
Ekomont, Enel, Termovod, Siemens-Landis&Staefa, Enikon, Tehnomobil, Tehnika |
63 |
and others. During the design and construction, PLIVA placed special attention |
64 |
on environmental protection issues. Production has no affects on the environment, |
65 |
and all waste resulting from production is treated according to the highest |
66 |
international environmental standards.<br> |
67 |
<br> |
68 |
Commenting on the significance of this facility for PLIVA’s operations in |
69 |
the future, PLIVA’s CEO Zeljko Covic stressed: “Owing to the fact that it |
70 |
meets the highest standards of Good Manufacturing Practice, the most important |
71 |
feature of this new facility is that it will enable the production of finished |
72 |
drug forms to be exported to the demanding West European and US markets. |
73 |
With the construction of the new Oral Solid Dosage Forms facility, PLIVA |
74 |
has met the demands of the market that requires a wide range of high quality |
75 |
pharmaceutical products, with the highest standards of safety at work, environmental |
76 |
protection and energy management. This fulfills PLIVA’s vision – to be a |
77 |
pharmaceutical company bringing superior and innovative solutions to customer |
78 |
needs, by competing in the global market.”<br> |
79 |
</body> |
80 |
</html> |